AB Science provides an update on its masitinib clinical program
August 05, 2019 01:31 ET
|
AB Science
Paris, August 5 2019, 7.30am Update on masitinib clinical program AB Science SA (NYSE Euronext - FR0010557264 - AB) provides an update on its masitinib clinical program. The key points of...
AB Science annonce aujourd’hui les résultats de son étude de phase 3 évaluant le masitinib chez des patients atteints de mélanome non opérable ou métastatique de stade 3 ou stade 4
August 02, 2019 11:44 ET
|
AB Science
Paris, 2 août 2019, 17h30 AB Science annonce de nouveaux résultats cliniques en oncologie :L’activité du masitinib a été démontrée dans le mélanome métastatiqueprésentant une mutation du domaine...
AB Science today reports the analysis for its phase 3 trial evaluating masitinib in patients with non-resectable or metastatic stage 3 or stage 4 melanoma
August 02, 2019 11:44 ET
|
AB Science
Paris, August 2, 2019, 5.30pm AB Science announces new clinical results in oncology: Masitinib showed activity in metastatic melanoma bearingthe juxta-membrane mutation of c-Kit AB...
Organovo Affirms Key Clinical Development Goals; Company Reports Fiscal Second-Quarter 2019 Results
November 08, 2018 16:05 ET
|
Organovo, Inc.
Pre-Investigational New Drug (“IND”) meeting with the FDA expected to be held in calendar 2019Second orphan designation anticipated in first half of calendar 2019Submit first IND in calendar 2020 ...
Achillion Announces ACH-4471 Receives Positive Opinion for Orphan Drug Designation in the European Union for the Treatment of C3 Glomerulopathy
February 26, 2018 06:05 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a biopharmaceutical company focused on advancing small molecule factor D inhibitors to modulate the...
Protalix BioTherapeutics to Hold Full-Year 2016 Financial Results and Corporate Update Conference Call on March 16, 2017
March 09, 2017 07:30 ET
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, March 09, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of...
XOMA Announces Significant Step Toward Initiating Pediatric Phase 2 Clinical Study for XOMA 358 in Children with Congenital Hyperinsulinism
October 19, 2016 09:00 ET
|
XOMA Ltd.
BERKELEY, Calif., Oct. 19, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today the United Kingdom’s...
Achillion Reports Second Quarter 2016 Financial Results
August 04, 2016 16:05 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn. , Aug. 04, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and six months ended June 30, 2016. For the second...
Achillion Announces Upcoming Oral Presentation at the 57th Annual Meeting of the American Society of Hematology and Nomination of ACH-4471, a Novel Small Molecule Factor D Inhibitor, for Clinical Development
December 05, 2015 17:00 ET
|
Achillion Pharmaceuticals, Inc.
- Presentation will highlight ACH-4471, a highly potent, specific, and orally-administered factor D inhibitor, and preclinical data on its ability to block hemolysis of paroxysmal nocturnal...
Achillion Reports Third Quarter And Nine Month 2015 Financial Results
November 05, 2015 17:51 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Nov. 05, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and nine months ended September 30, 2015. For the...